H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Santhera Pharmaceuticals Holding (SPHDF – Research Report) today and set a price target of CHF30.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors including the commercial traction of Santhera Pharmaceuticals’ product, vamorolone, and its promising financial outlook. The recent availability of funding from the National Health Service in England for AGAMREE, a treatment for Duchenne muscular dystrophy, marks a significant milestone, allowing prescribing in England to begin. This development, coupled with the acceptance by Health Canada for AGAMREE’s New Drug Submission with Priority Review, positions the therapy as a potential first DMD drug approved in Canada by the end of 2025.
Furthermore, Santhera’s strategic engagement in health technology assessments, pricing negotiations, and reimbursement decisions across key European markets is expected to drive further growth. The company anticipates significant revenue increases, with projections of CHF68M in 2025 and potential growth to CHF110M by 2026. With a healthy balance sheet and sufficient cash reserves to support operations until cash flow breakeven, expected by the first half of 2026, Santhera is well-positioned for continued success, justifying the Buy rating and an increased price target of CHF30.
According to TipRanks, Selvaraju is a 4-star analyst with an average return of 7.7% and a 38.85% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Niagen Bioscience, Rhythm Pharmaceuticals, and Emergent Biosolutions.